Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?

Mint - Oct 29, 2026

Retatrutide is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro.

Read full article

More News

Still Surge

Let your "surge" of emotions burst forth when reading the news articles acknowledging the beauty and vastness of Science and futuristic Technologies.

NEWSLETTER